Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE™ (setmelanotide) as First-ever Therapy for Chronic Weight Management in Patients with Obesity Due to POMC, PCSK1 or LEPR Deficiency
This week, Rhythm Pharmaceuticals, a biopharmaceutical company specializing in the treatment of rare genetic diseases surrounding obesity, announced the U.S. […]